secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001396814-25-000100
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira Q2 2025 revenue $181.1M, GAAP net loss $4.8M; guidance updated, legal win $28.3M
--------------------------------------------------------------------------------

- Total revenues $181.1M (+2% YoY); EXPAREL $142.9M, ZILRETTA $31.3M, iovera° $5.6M.
- GAAP net loss $4.8M ($0.11/share) vs net income $18.9M in Q2 2024; non-GAAP net income $36.0M.
- Received $28.3M from favorable court ruling on EXPAREL royalty repayment from RDF in July 2025.
- New $300M five-year revolving credit facility replaces prior term loan; reduces interest expense 60bps in 2026.
- 2025 guidance: revenue narrowed to $730M-$750M; non-GAAP gross margin raised to 78-80%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681425000100/0001396814-25-000100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681425000100/pcrx-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001396814-25-000100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer